Back to list

Mark Wade

Senior Researcher

Former colleague






Bachelor of Science (First Class, Honors), University of Bath, UK (1997). Molecular and Cellular Biology.

Doctor of Philosophy, Imperial College, London, UK (2001): Virology and Cell Biology. Genotoxin-induced apoptosis in human lymphoid cells. Advisor: Professor Martin J Allday

Research and training

Senior Research Associate, Wahl Lab, Salk Institute for Biological Studies, USA. (2007-March 2011). Development and validation of cell based screens to interrogate the p53 pathway and screen for p53-activating molecules. Author on 7 peer-reviewed articles.

Postdoctoral Research Fellow, Wahl Lab, Salk Institute for Biological Studies, USA. (2001-2006). Focus on oncogene-induced DNA damage, and oncogenic suppression of p53 tumor suppressor activity. Author on 5 peer reviewed articles






Screening Unit


Functional genomic and small molecule screens in cell based assays

We have established collaborative projects with other groups at the Center for Genomic Science of IIT@SEMM

We welcome proposals for cell-based screens from other IIT Centers/Departments and external collaborators

Internal Projects


Strong focus on the role of mitochondrial outer membrane proteins in apoptosis

Development of screens to identify mediators of both sensitivity and resistance to clinically-relevant mitochondrial-targeted agents

Development of cell-based assays for interrogating protein-protein interaction

Therapeutic areas of interest: Oncology and Neurodegeneration

Selected Publications

Wade M, Li YC and Wahl GM (2013). MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Reviews Cancer 2013 Feb;13(2):83-96. doi: 10.1038/nrc3430.

Wade M, Li YC, Matani AS, Braun SM, Milanesi F, Rodewald LW, Wahl GM. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells. Oncogene 2012 Jan 23. doi: 10.1038/onc.2011.625.

Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL Wahl GM and Walensky LD (2010).A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53. Cancer Cell 18(5):411-22.

Wade M, Wang YV and Wahl GM (2010). The p53 orchestra: mdm2 and mdmx set the tone. Trends in Cell Biology 20(5):299-309.

Wang YV, Wade M and Wahl GM (2009). Guarding the Guardian: Mdmx plays important roles in setting p53 basal activity and determining biological responses in vivo. Cell Cycle 6;8(21).

Wang YV, LeBlanc M, Wade M, Jochemsen A and Wahl GM (2009). Increased radio-resistance and accelerated B-cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA damage-activated kinases. Cancer Cell Jul 7;16(1):33-43

Wade M and Wahl GM (2009). Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7: 1-11 (Most highly cited article in this journal for 2009)

Wade M, Rodewald LW, Espinosa JM and Wahl GM (2008). BH3 activation blocks Hdmx suppression of apoptosis and co-operates with Nutlin to induce cell death. Cell Cycle July 1:7;(13):1973-82.

Wang Y, Wade M, Wong ET, Li YC, Rodewald LW, and Wahl GM (2007). Quantitative analyses reveal the importance of regulated Hdmx degradation for P53 activationPNAS Jul 24;104(30):12365-70

Leao M, Anderton E, Wade M, Meekings K, and Allday MJ (2006). Epstein-Barr virus (EBV)-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J. Virol. 2007 Jan;81(1):248-60. Epub 2006 Oct 11

Wade M, Wong ET, Tang M, Stommel JM and Wahl GM (2006). Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem Nov 3;281(44):33036-44. Epub Aug 13.

Wade M and Wahl GM (2006). c-Myc, Genome Instability, and Tumorigenesis: The Devil is in the Details. In “The Myc/Max/Mad Transcription Factor Network”. Editor Robert Eisenman. Current Topics in Microbiology and Immunology Vol 302. pp169-203. Publisher: Springer-Verlag.

Wahl GM, Stommel JM, Krummel KA and Wade M (2005) Gatekeepers of the guardian: p53 regulation by post-translational modification, mdm2 and mdmx. In "25 Years of p53 Research". Chapter 4:73-113. Editors: Klas Wiman and Pierre Hainaut. Publisher: Springer-Verlag

Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9(5):1031-44.

Wade M and Allday MJ (2000). Epstein-Barr virus abrogates a G2/M checkpoint activated by genotoxins. Mol Cell Biol. 2000 Feb;20(4):1344-60.

Walsh DA, Wade M, Mapp PI and Blake DR (1998). Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol 152(3):691-702


Patent application US2011/060647: Compositions and Methods for increasing p53 activity in cell

First prize for poster at the 5th International Mdm2 Workshop, Gent, Belgium (2009).

AACR Young Investigator Award at the 4th International Mdm2 Workshop, Woods Hole, MA, USA (2007).


IIT's website uses the following types of cookies: browsing/session, analytics, functional and third party cookies. Users can choose whether or not to accept the use of cookies and access the website. By clicking on "Further Information", the full information notice on the types of cookies will be displayed and you will be able to choose whether or not to accept them whilst browsing on the website
Further Information
Accept and close

I numeri di IIT

L’Istituto Italiano di Tecnologia (IIT) è una fondazione di diritto privato - cfr. determinazione Corte dei Conti 23/2015 “IIT è una fondazione da inquadrare fra gli organismi di diritto pubblico con la scelta di un modello di organizzazione di diritto privato per rispondere all’esigenza di assicurare procedure più snelle nella selezione non solo nell’ambito nazionale dei collaboratori, scienziati e ricercatori ”.

IIT è sotto la vigilanza del Ministero dell'Istruzione, dell'Università e della Ricerca e del Ministero dell'Economia e delle Finanze ed è stato istituito con la Legge 326/2003. La Fondazione ha l'obiettivo di promuovere l'eccellenza nella ricerca di base e in quella applicata e di favorire lo sviluppo del sistema economico nazionale. La costruzione dei laboratori iniziata nel 2006 si è conclusa nel 2009.

Lo staff complessivo di IIT conta circa 1440 persone. L’area scientifica è rappresentata da circa l’85% del personale. Il 45% dei ricercatori proviene dall’estero: di questi, il 29% è costituito da stranieri provenienti da oltre 50 Paesi e il 16% da italiani rientrati. Oggi il personale scientifico è composto da circa 60 principal investigators, circa 110 ricercatori e tecnologi di staff, circa 350 post doc, circa 500 studenti di dottorato e borsisti, circa 130 tecnici. Oltre 330 posti su 1400 creati su fondi esterni. Età media 34 anni. 41% donne / 59 % uomini.

Nel 2015 IIT ha ricevuto finanziamenti pubblici per circa 96 milioni di euro (80% del budget), conseguendo fondi esterni per 22 milioni di euro (20% budget) provenienti da 18 progetti europei17 finanziamenti da istituzioni nazionali e internazionali, circa 60 progetti industriali

La produzione di IIT ad oggi vanta circa 6990 pubblicazioni, oltre 130 finanziamenti Europei e 11 ERC, più di 350 domande di brevetto attive, oltre 12 start up costituite e altrettante in fase di lancio. Dal 2009 l’attività scientifica è stata ulteriormente rafforzata con la creazione di dieci centri di ricerca nel territorio nazionale (a Torino, Milano, Trento, Parma, Roma, Pisa, Napoli, Lecce, Ferrara) e internazionale (MIT ed Harvard negli USA) che, unitamente al Laboratorio Centrale di Genova, sviluppano i programmi di ricerca del piano scientifico 2015-2017.

IIT: the numbers

Istituto Italiano di Tecnologia (IIT) is a public research institute that adopts the organizational model of a private law foundation. IIT is overseen by Ministero dell'Istruzione, dell'Università e della Ricerca and Ministero dell'Economia e delle Finanze (the Italian Ministries of Education, Economy and Finance).  The Institute was set up according to Italian law 326/2003 with the objective of promoting excellence in basic and applied research andfostering Italy’s economic development. Construction of the Laboratories started in 2006 and finished in 2009.

IIT has an overall staff of about 1,440 people. The scientific staff covers about 85% of the total. Out of 45% of researchers coming from abroad 29% are foreigners coming from more than 50 countries and 16% are returned Italians. The scientific staff currently consists of approximately 60 Principal Investigators110 researchers and technologists350 post-docs and 500 PhD students and grant holders and 130 technicians. External funding has allowed the creation of more than 330 positions . The average age is 34 and the gender balance proportion  is 41% female against 59% male.

In 2015 IIT received 96 million euros in public funding (accounting for 80% of its budget) and obtained 22 million euros in external funding (accounting for 20% of its budget). External funding comes from 18 European Projects, other 17 national and international competitive projects and approximately 60 industrial projects.

So far IIT accounts for: about 6990 publications, more than 130 European grants and 11 ERC grants, more than 350 patents or patent applications12 up start-ups and as many  which are about to be launched. The Institute’s scientific activity has been further strengthened since 2009 with the establishment of 11 research nodes throughout Italy (Torino, Milano, Trento, Parma, Roma, Pisa, Napoli, Lecce, Ferrara) and abroad (MIT and Harvard University, USA), which, along with the Genoa-based Central Lab, implement the research programs included in the 2015-2017 Strategic Plan.